Blog

Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a much-needed off-the-shelf treatment option for people…
Leer más...

BIG3 Announces Miami Expansion in $10 Million Deal

LOS ANGELES--(BUSINESS WIRE)--Today, the BIG3 announced that a group of investors led by media, sports, real estate, and hospitality executive Heath Freeman has purchased the rights to the second-ever location-based BIG3 franchise with plans to base the team in Miami. Freeman will take ownership for the 2025 season, when all…
Leer más...

SMG INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that The Scotts Miracle-Gro Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers of The Scotts Miracle-Gro Company (NYSE: SMG) common stock between November 3, 2021 and August 1, 2023, both dates inclusive (the “Class Period”), have until August 5, 2024 to seek appointment as lead plaintiff of the Scotts Miracle-Gro class…
Leer más...

Sparrow Pharmaceuticals Presents Data from Ongoing Phase 2 Trial of Clofutriben (SPI-62) and Prednisolone as a Treatment for Polymyalgia Rheumatica at EULAR 2024

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals today presented data from an ongoing Phase 2 clinical trial of HSD-1 inhibitor clofutriben (SPI-62) and prednisolone in patients with polymyalgia rheumatica (PMR) at the 2024 Annual European Alliance for Associations for Rheumatology (EULAR 2024; June 12 – 15 in Vienna, Austria) that suggest HSD-1 inhibition…
Leer más...

Energy Transfer and Crestwood Schedule K-3s for 2023 Now Available

DALLAS--(BUSINESS WIRE)--Energy Transfer LP (NYSE: ET) today announced that Energy Transfer LP and Crestwood Equity Partners LP 2023 Schedule K-3s reflecting items of international tax relevance are available online. Unitholders requiring this information may access their Schedule K-3 at www.energytransfer.com in the investor relations section of the website. A limited…
Leer más...